Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 145–156 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

NCT05978713
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions
Gastric Fundal Mucosal Ablation (GFMA)
Device
Lead sponsor
Dr. Christopher McGowan
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418
View directory record Official record
Conditions
Obesity
Interventions
Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
55 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

NCT06565611
View directory record Official record
Conditions
Obesity
Interventions
bremelanotide, tirzepatide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

NCT06009653
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
View directory record Official record
Conditions
OSA
Interventions
AD109
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

NCT06761703
View directory record Official record
Conditions
Obesity
Interventions
TAP® Micro Select Device (Touch Activated Phlebotomy)
Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 6:56 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

NCT05706506
View directory record Official record
Conditions
Type 2 Diabetes, Diabetes Mellitus, Type 2
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
32
States / cities
Tempe, Arizona • Corona, California • Gardena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 20, 2026, 6:56 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

NCT05912621
View directory record Official record
Conditions
Obesity, Overweight and Obesity, Overweight
Interventions
Tirzepatide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

NCT05810597
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
South Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 20, 2026, 6:56 AM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 20, 2026, 6:56 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.